Data / Drug companies / Par Health USA, LLC
Par Health USA, LLC: 100 products in the FDA NDC directory, labeler code 49884
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Par Health USA, LLC (labeler code 49884) lists 100 products in the FDA National Drug Code Directory, covering 38 finished drugs by generic name. By type: 100 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 17, 2025.
The request: Watch Par Health USA, LLC (FDA labeler code 49884): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 49884
- Products in commercial distribution
- 100
- Packages
- 124
- Finished drugs by generic name
- 38
- Prescription products
- 100
- Over the counter products
- 0
- Controlled substance products
- Schedule II 8, Schedule IV 11
- Flagged as original packager
- 92 of 92 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 2
- Earliest marketing start
- December 13, 1979
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 96 | 96% |
| Authorized generics (NDA) | 3 | 3% |
| New drug applications (NDA) | 1 | 1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 100 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Dexmethylphenidate hydrochloride | 8 | 17 |
| Lamotrigine | 7 | 51 |
| Risperidone | 6 | 43 |
| Clonazepam | 5 | 36 |
| Isosorbide dinitrate | 5 | 18 |
| Olanzapine and fuoxetine | 5 | 1 |
| Cholestyramine | 4 | 14 |
| Alprazolam | 4 | 37 |
| Glycopyrrolate | 3 | 64 |
| Dantrolene sodium | 3 | 14 |
| Midodrine hydrochloride | 3 | 34 |
| Varenicline tartrate | 3 | 23 |
| Sapropterin dihydrochloride | 3 | 10 |
| Minoxidil | 2 | 113 |
| Tolvaptan | 2 | 9 |
| Everolimus | 2 | 15 |
| Fluoxetine hydrochloride | 2 | 44 |
| Ursodiol | 2 | 28 |
| Aliskiren | 2 | 1 |
| Zolpidem tartrate sublingual | 2 | 1 |
| Pimozide | 2 | 2 |
| Dexlansoprazole | 2 | 12 |
| Amiloride hydrochloride | 1 | 4 |
| Vigabatrin | 1 | 18 |
| Ibuprofen and famotidine | 1 | 14 |
| Sodium phenylbutyrate | 1 | 7 |
| Cyanocobalamin | 1 | 25 |
| Fluoxetine | 1 | 42 |
| Glycerol phenylbutyrate oral | 1 | 2 |
| Hydroxyurea | 1 | 14 |
| Diclofenac potassium | 1 | 42 |
| Sodium phenylbutyrate tablets, 500 mg | 1 | 1 |
| Colchicine | 1 | 34 |
| Penicillamine | 1 | 12 |
| Praziquantel | 1 | 2 |
| Calcitonin salmon | 1 | 13 |
| Aspirin and extended - release dipyridamole | 1 | 2 |
| Trientine hydrochloride | 1 | 7 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 24 | 24% |
| Tablet, orally disintegrating | 19 | 19% |
| Tablet, film coated | 14 | 14% |
| Capsule | 13 | 13% |
| Capsule, extended release | 8 | 8% |
| Powder, for suspension | 4 | 4% |
| Kit | 4 | 4% |
| Powder, for solution | 4 | 4% |
| Tablet, coated | 2 | 2% |
| Capsule, delayed release | 2 | 2% |
| Tablet, delayed release | 1 | 1% |
| Powder | 1 | 1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Glycerol Phenylbutyrate | 49884-264 | Liquid | Generic drugs (ANDA) | October 17, 2025 |
| Ibuprofen and famotidine | 49884-366 | Tablet | Generic drugs (ANDA) | March 22, 2024 |
| Dexlansoprazole | 49884-147 | Capsule, delayed release | Generic drugs (ANDA) | June 10, 2023 |
| Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride | 49884-151 | Capsule | Generic drugs (ANDA) | March 7, 2023 |
| Diclofenac Potassium | 49884-905 | Powder, for solution | Generic drugs (ANDA) | January 3, 2023 |
| Dexlansoprazole | 49884-148 | Capsule, delayed release | Generic drugs (ANDA) | November 22, 2022 |
| Colchicine | 49884-171 | Tablet, film coated | Generic drugs (ANDA) | September 27, 2022 |
| Everolimus | 49884-159 | Tablet | Generic drugs (ANDA) | March 31, 2022 |
| Tolvaptan | 49884-770 | Tablet | Generic drugs (ANDA) | March 10, 2022 |
| Tolvaptan | 49884-768 | Tablet | Generic drugs (ANDA) | March 10, 2022 |
| Everolimus | 49884-283 | Tablet | Generic drugs (ANDA) | January 26, 2022 |
| Glycopyrrolate | 49884-042 | Solution | Generic drugs (ANDA) | January 4, 2022 |
| Isosorbide Dinitrate | 49884-556 | Tablet | Generic drugs (ANDA) | December 21, 2021 |
| Varenicline | 49884-944 | Kit | Generic drugs (ANDA) | September 21, 2021 |
| Varenicline | 49884-156 | Tablet, film coated | Generic drugs (ANDA) | September 21, 2021 |
| Varenicline | 49884-155 | Tablet, film coated | Generic drugs (ANDA) | September 21, 2021 |
| Sapropterin dihydrochloride | 49884-948 | Powder, for solution | Generic drugs (ANDA) | October 1, 2020 |
| Sapropterin dihydrochloride | 49884-873 | Powder, for solution | Generic drugs (ANDA) | October 1, 2020 |
| Sapropterin dihydrochloride | 49884-720 | Tablet | Generic drugs (ANDA) | October 1, 2020 |
| Penicillamine | 49884-146 | Capsule | Generic drugs (ANDA) | January 8, 2020 |
| Doxylamine Succinate and Pyridoxine Hydrochloride | 49884-186 | Tablet, delayed release | Generic drugs (ANDA) | December 19, 2019 |
| Trientine Hydrochloride | 49884-060 | Capsule | Generic drugs (ANDA) | September 27, 2019 |
| Aliskiren | 49884-425 | Tablet, film coated | Generic drugs (ANDA) | March 25, 2019 |
| Aliskiren | 49884-424 | Tablet, film coated | Generic drugs (ANDA) | March 25, 2019 |
| Midodrine Hydrochloride | 49884-874 | Tablet | Generic drugs (ANDA) | October 29, 2018 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.